Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies
Authors:
Open Access
- 3 August 2026
- journal article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (5) , 106895
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Secondary prevention with antiplatelet medications in patients with antiphospholipid antibody-related strokeScientific Reports, 2025
- An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid AntibodiesJournal of Thrombosis and Haemostasis, 2024
- Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic strokeJournal of Stroke and Cerebrovascular Diseases, 2024
- Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndromeScientific Reports, 2023
- Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid SyndromesJACC, 2022
- Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic strokeJournal of Neurology, 2021
- Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated StrokeJAMA Neurology, 2020
- Embolic strokes of undetermined source: the case for a new clinical constructThe Lancet Neurology, 2014
- Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic StrokeJAMA, 2004
- A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic StrokeNew England Journal of Medicine, 2001